Genomic Analysis Reveals the Molecular Heterogeneity of Ovarian Clear Cell Carcinomas
David S.P. Tan(National University of Singapore), Jorge S. Reis‐Filho(AstraZeneca (France)), C. Gourley(Edinburgh Cancer Research), Hani Gabra(Royal Children's Hospital), Karen Thomas(Royal Glamorgan Hospital), Rachael Natrajan(Institute of Cancer Research), Marjan Iravani(Institute of Cancer Research), Charles Jameson(Royal London Hospital), Mona El‐Bahrawy(Al-Azhar University), Alan Mackay(Institute of Cancer Research), Kay Savage(Institute of Cancer Research), A. Wynn Williams(University of Edinburgh), Kerry Fenwick(Institute of Cancer Research), Joanne Millar(Belfast Health and Social Care Trust), Felipe C. Geyer(Institute of Cancer Research), Alan Ashworth(University of California, San Francisco), Stanley B. Kaye(Royal Marsden Hospital), Radost Vatcheva(Institute of Cancer Research), Maryou B. Lambros(Institute of Cancer Research), W. Glenn McCluggage(Belfast Health and Social Care Trust), Martin Gore(Imperial College London), Fernanda Milanezi(Universidade do Porto)
Cited by 146
Related Papers
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma
|Cancer Cell|2017|1.3k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k